
Thermo Fisher Scientific MCP-2 Polyclonal Antibody
인간 MCP-2를 인식하는 염소 다클론 항체로, Western blot, ELISA, 중화시험에 사용 가능. 항원 친화 크로마토그래피로 정제된 액상 형태이며, PBS 버퍼에 보존제 없이 제공. 연구용으로만 사용.
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific MCP-2 Polyclonal Antibody
Applications and Tested Dilution
| Application | Tested Dilution |
|---|---|
| Western Blot (WB) | 0.1–0.2 µg/mL |
| ELISA | 0.5–1 µg/mL |
| Neutralization (Neu) | 2–5 µg/mL |
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Goat / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | Purified, E. coli-derived, recombinant human MCP2 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Concentration | 0.1 mg/mL |
| Purification | Antigen affinity chromatography |
| Storage Buffer | PBS |
| Contains | No preservative |
| Storage Conditions | 4°C, do not freeze |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
| RRID | AB_779579 |
Product Specific Information
The ND50 is approximately 2–5 µg/mL in the presence of 0.4 µg/mL of human MCP2, using the human monocyte chemotaxis assay.
Target Information
This antimicrobial gene is one of several chemokine genes clustered on the q-arm of chromosome 17. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. This chemokine is a member of the CC subfamily, characterized by two adjacent cysteine residues. It displays chemotactic activity for monocytes, lymphocytes, basophils, and eosinophils. By recruiting leukocytes to sites of inflammation, it may contribute to tumor-associated leukocyte infiltration and to the antiviral state against HIV infection.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
